FFF Enterprises Delivers Coagulation Products to Patients Who Need Them Most

FFF Enterprises in Temecula, CA, is the nation’s most trusted distributor of critical care biopharmaceuticals, including life-giving coagulation products. Coagulation products (also known as factor) are proteins in blood plasma that are responsible for effective clotting of blood. These products are used to help patients who are born with an inherited deficiency of plasma proteins necessary for blood coagulation or clotting, which leads to increased risk of dangerous, uncontrolled bleeding. There are numerous coagulation disorders stemming from a variety of causes.

The most commonly known coagulation disorder treated with coagulation products is hemophilia A. Hemophilia patients can bleed for long periods of time before blood clotting occurs. Hemophilia A is carried by females but primarily affects males. Hemophilia is caused by a factor VIII deficiency.

Hemophilia B, is a factor IX deficiency, and while less common, has similar symptoms to hemophilia A that are also treated with coagulation products. Factor IX is produced in the liver and is dependent on interaction with vitamin K in order to function properly, so a deficiency in this vitamin can affect the clotting factor’s performance as well as deficiency in the factor itself.

Coagulation products are used to treat Thrombpocytopenia, the most common cause of coagulation disorder, which is characterized by reduced numbers of circulating platelets in the blood. This disease also includes idiopathic thrombocytopenia.

Another rare bleeding disorder treated with coagulation products is von Willebrand disease. Von Willebrand disease is also an inherited disorder that affects the blood’s ability to clot properly. It is named for Dr. Erik von Willebrand, who first described the condition in 1926. Von Willebrand disease is the most common inherited bleeding disorder, affecting as much as one percent of the population. Unlike hemophilia, which affects only boys, von Willebrand affects boys and girls equally.

Other coagulation disorders include factor XI deficiency (hemophilia C), and factor VII deficiency. Hemophilia C afflicts one in 100,000 people and is the second most common bleeding disorder among women. Factor VII is also called serum prothrombin conversion accelerator (SPCA) deficiency. One in 500,000 people may be afflicted with this disorder that is often diagnosed in newborns because of bleeding into the brain following traumatic delivery.

FFF Enterprises is the nation's leading supplier of critical-care biopharmaceuticals, plasma products (including albumin, intravenous immune globulin and coagulation products) and vaccines. As a trusted distributor, FFF Enterprises continues to set the standard for patient safety, access and availability to the coagulation products that improve the quality of life for the patients who receive them.

About the Author:

FFF Enterprises is the author of this article on Coagulation Products. Find more information about Critical Care Biopharmaceuticals here.